AGP Executive Report
Last update: 5 minutes agoDrug Supply: India’s pharma industry is seeking clarity on new batch-by-batch clearance rules for high-risk solvents, warning that delays could disrupt manufacturing and medicine supplies, including exports. Quality Standards: Pakistani drugmaker Getz Pharma won WHO prequalification for a second manufacturing site, a boost for its export prospects and the country’s medicines industry. Preventive Care Oversight: Ethics waivers allow four of eight new U.S. Preventive Services Task Force members to keep shares in drug and health companies affected by the panel’s recommendations, prompting concerns about conflicts of interest. Heart Drug Trials: Pelacarsen sharply lowered Lp(a) but did not reduce major cardiovascular events in a large trial, underscoring the gap between improving a biomarker and preventing heart attacks and strokes. Care Access: Rising ACA premiums are pushing some people toward less coverage or no insurance, while growing demand for medical flights in rural Maine highlights how hospital closures can leave patients farther from care.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[Building Systems to Catch Liver and Other Cancers in Patients With MASLD]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/30179640-955425299-c77be6d710fe607d94ff102e806db8cfb868b932-1200x1427-168x200.jpeg)
![<![CDATA[Closing the Gap Between Tumor Board Recommendations and Liver Cancer Care]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/30179647-955425297-2e9a0fc562e4c698f0f31b03d24001b7054a2663-1920x1080-200x113.png)
